GRG's Center For Experiential Learning

Metastatic melanoma was once a near-certain death sentence, but PD-1/PD-L1 inhibitors have rewritten the story. From survival rates once measured in months to long-term remission and renewed hope, immune checkpoint therapies like nivolumab and pembrolizumab are transforming cancer care and reshaping the future of oncology.

Emerging therapies like complement and FcRn inhibitors are reshaping Myasthenia Gravis care, offering more targeted and effective options for patients. But with challenges in diagnosis, access, and long-term safety still in play, the road ahead demands innovation, collaboration, and a patient-centered approach.